The effects of transurethral resection of the prostate on morbidity and mortality in patients with nondialysis-requiring renal insufficiency


Creative Commons License

Akdemir A. O. , Oztekin C. V. , Doluoglu O. G. , Karabakan M., UĞURLU Ö., Cetinkaya M.

Therapeutic Advances in Urology, vol.4, no.2, pp.51-56, 2012 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 2
  • Publication Date: 2012
  • Doi Number: 10.1177/1756287211435088
  • Journal Name: Therapeutic Advances in Urology
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.51-56
  • Keywords: uremia, prostatic hyperplasia, transurethral resection of prostate, renal dialysis
  • Lokman Hekim University Affiliated: Yes

Abstract

Objectives: To compare the prevalence of preoperative co-morbid factors and complications of transurethral resection of prostate (TUR-P) in patients with normal and non-dialysis requiring elevated serum creatinine levels. Methods: The records of 357 consecutive patients with IPSS≤20, serum creatinine level ≤ 3 mg/dl, residual urine volume ≤ 300 ml and with no upper urinary tract dilatation or evidence of prostate cancer that underwent TUR-P were retrospectively evaluated. 60 patients who did not fulfill the inclusion criteria were excluded. The preoperative Na, K, creatinine levels and the early changes observed in these parameters after TUR-P of the patients with normal (Group1, n = 272) and elevated (Group2, n = 25) serum creatinine levels, as well as the preoperative baseline data and postoperative complications were compared. Results: Preoperative PSA, serum urea, creatinine and K levels were significantly higher in group2. No significant differences were observed between early and late postoperative complications of the two groups. Co-morbid diseases were significantly more common in group2. No progression in renal failure or de novo need for hemodialysis was observed in group2. Conclusions: TUR-P can be safely performed in BPH patients with mild serum creatinine elevations (1.6-3 mg/dl) and moderately increased prostate volumes without additional morbidity and mortality. © 2012, SAGE Publications. All rights reserved.